Jpmorgan Chase & CO Arcellx, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Arcellx, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 250,123 shares of ACLX stock, worth $20.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

250,123

Previous 261,359 4.3%

Holding current value

$20.5 Million

Previous $14.4 Million 44.81%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$50.91 - $86.61 $572,024 - $973,149	-11,236 Reduced 4.3%	250,123 $20.9 Million
Q2 2024 Aug 12, 2024	SELL	$49.74 - $66.98 $14.4 Million - $19.5 Million	-290,391 Reduced 52.63%	261,359 $14.4 Million
Q1 2024 May 10, 2024	SELL	$51.85 - $73.49 $2.6 Million - $3.69 Million	-50,163 Reduced 8.33%	551,750 $38.4 Million
Q4 2023 Feb 12, 2024	BUY	$31.75 - $57.99 $1.21 Million - $2.2 Million	38,014 Added 6.74%	601,913 $33.4 Million
Q3 2023 Nov 14, 2023	BUY	$31.51 - $37.4 $7.45 Million - $8.84 Million	236,461 Added 72.22%	563,899 $20.2 Million
Q2 2023 Aug 11, 2023	SELL	$27.49 - $46.9 $6.1 Million - $10.4 Million	-221,759 Reduced 40.38%	327,438 $10.4 Million
Q1 2023 May 18, 2023	BUY	$26.92 - $33.94 $968,312 - $1.22 Million	35,970 Added 7.01%	549,197 $16.9 Million
Q1 2023 May 11, 2023	SELL	$26.92 - $33.94 $6.21 Million - $7.83 Million	-230,771 Reduced 31.02%	513,227 $15.8 Million
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $10.2 Million - $19.5 Million	590,980 Added 386.22%	743,998 $23 Million
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $473,628 - $626,200	28,412 Added 22.8%	153,018 $2.87 Million
Q2 2022 Aug 11, 2022	BUY	$7.21 - $24.43 $867,651 - $2.94 Million	120,340 Added 2820.91%	124,606 $2.25 Million
Q1 2022 May 11, 2022	BUY	$12.97 - $19.14 $55,330 - $81,651	4,266 New	4,266 $60,000

Others Institutions Holding ACLX

# of Institutions

205

Shares Held

44.2M

Call Options Held

2.23M

Put Options Held

907K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $3.6B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Arcellx, Inc. Transaction History